首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2092264

節肢動物傳播病毒感染疾病市場：全球市場預測（2026-2032）

Arthropod-borne Viral Infections Testing Market - Global Forecast 2026-2032

出版日期: 2026年07月16日 | 出版商:

360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

預計到 2032 年，節肢動物傳播病毒感染疾病市場將成長至 19.9 億美元，複合年成長率為 7.36%。

主要市場統計數據
基準年（2025 年）	12.1億美元
預計年份（2026年）	12.9億美元
預測年份（2032年）	19.9億美元
複合年成長率（）	7.36%

隨著登革熱、屈公病、茲卡熱、黃熱病、日本腦炎、西尼羅河病毒、蜱傳腦炎和其他蟲媒病毒感染疾病在流行地區和新出現的高風險地區蔓延，節肢動物傳播的病毒感染疾病已成為全球感染疾病防治的關鍵支柱。這些感染疾病主要透過蚊子、蜱蟲、獵蝽和其他媒介傳播，其風險受都市化、氣候變遷、國際移民、土地利用變化、媒介控制不力以及人群免疫狀況的影響。許多蟲媒病毒感染疾病的症狀重疊，包括發燒、皮疹、關節痛、肌肉痛、頭痛和神經系統併發症，因此僅憑症狀診斷不足以進行臨床管理和公共衛生應對；準確快速的診斷檢測至關重要。

診斷策略日益融合集體爆發確認、監測、血液安全、疫苗接種策略以及與瘧疾、鉤端螺旋體病、基因測序樣疾病和其他發熱性疾病的鑑別診斷。核酸增幅檢查在病毒血症早期最為有效，而IgM和IgG血清學檢測在急性期過後變得至關重要。然而，黃病毒之間的交叉反應仍然是一個公認的挑戰，尤其是在登革熱、茲卡和黃熱病疫苗接種與日本腦炎暴露並存的地區。隨著快速檢測和強力的監測成為醫療保健系統的優先事項，對可靠的蟲媒病毒診斷的需求受到檢查室能力、即時檢測的可及性、品質保證、監管監督以及與國家疾病報告系統的整合等因素的影響。

蟲媒病毒檢測領域的變革性變化

受多種因素驅動，節肢動物傳播病毒感染疾病的市場格局正在轉變，這些因素包括控制高疾病負擔的地方性疾病的需求、氣候變遷導致的病媒擴張以及疫情資訊的快速收集。根據全球衛生組織報告，登革熱的發生率在近幾十年急劇上升，目前已有超過100個國家報告了病例。這凸顯了擴充性診斷方法的必要性，這些方法能夠區分登革熱與臨床表現相似的感染疾病。同時，西尼羅河病毒在溫帶地區的活動、屈公病在熱帶和亞熱帶地區的複發以及黃熱病在非洲和南美洲部分地區持續存在的風險，進一步強調了綜合蟲媒病毒監測的重要性。

人工智慧對蟲媒病毒診斷的累積影響

人工智慧整體透過增強疫情預測、診斷結果解讀、檢查室工作流程管理和監測分析，對節肢動物傳播的病毒感染疾病產生累積影響。人工智慧模型整合了媒介分佈、降雨量、溫度、濕度、遷移模式、土地利用、排水、臨床數據和實驗室報告數據，以識別高風險感染區域，從而支持早期療育。這對於登革熱、茲卡熱、屈公病、西尼羅河病毒和蜱傳腦炎尤其重要，因為這些疾病的媒介生態和季節性會影響檢測需求。

全球蟲媒病毒檢測的區域分析。

由於登革熱、日本腦炎和屈公病在熱帶和亞熱帶地區流行嚴重，以及茲卡病毒感染風險的日益增加，亞太地區仍然是節肢動物傳播病毒感染疾病最重要的地區之一。都市區密度、季風模式、埃及斑蚊族群成長以及城郊棲息地的擴張，持續推動東南亞、南亞和西太平洋部分地區的診斷需求。各國防控項目越來越依賴分子診斷確診試驗、NS1抗原檢測、IgM血清學檢測和哨點監測來支持集體爆發的發現和病例分類。

主要群體對蟲媒病毒檢測的優先順序

東南亞國協在節肢動物傳播病毒感染疾病領域佔有至關重要的地位。這是因為登革熱在多個成員國呈現高度流行狀態，而對屈公病、日本腦炎和茲卡病毒感染的監測仍是公共衛生領域的重要優先事項。人口的跨國流動、都市區密度以及季節性降雨使得檢查室報告的協調統一和區域集體爆發資訊的共用對於快速應對至關重要。

對節肢動物傳播病毒感染疾病的國家級分析

在美國，由於季節性西尼羅河病毒爆發、與旅行相關的登革熱和屈公病監測記錄、先天性茲卡病毒感染疾病以及對蜱傳病毒感染疾病日益成長的擔憂，亟需進行廣泛的蟲媒病毒檢測。加拿大則著重於西尼羅河病毒監測、旅遊醫學診斷以及蜱傳疾病監測，而墨西哥除了面臨嚴重的登革熱疫情外，還需要監測屈公病和茲卡病毒感染疾病。

為蟲媒病毒診斷領域的領導者提供的實用建議

產業領導者應優先開發和實施能夠應對蟲媒病毒感染疾病實際複雜性的診斷方法，例如病毒血症持續時間短、存在交叉反應抗體、合併感染病原體以及檢測資源分配不均等問題。多重檢測和血清學檢測方案的設計應基於當地的流行病學背景，最終的診斷流程應考慮黃病毒的交叉反應性和疫苗接種史。對不同人群、檢體類型和疾病階段的檢測方法進行檢驗至關重要，這有助於獲得可靠的結果。

基於證據的蟲媒病毒檢測和分析的分析方法

對節肢動物傳播病毒感染疾病的分析方法應整合檢驗的公共衛生證據、臨床診斷指南、流行病學監測數據、監管文件和同行評審的科學文獻。關鍵資訊來源包括權威衛生機構發布的疾病特定指南、國家監測快報、媒介分佈記錄、關於檢測演算法和檢測性能的論文以及集體爆發報告。數據審查應重點關注已確診的疾病病例、診斷應用案例、檢測技術、檢體採集時間、區域疾病負擔趨勢和監測基礎設施。

結論：推廣蟲媒病毒檢測，以提高公共衛生應變能力。

隨著地方性疾病在全部區域加劇，並在受氣候變遷、人口遷移、都市化和生態系統變遷影響的新環境中出現，節肢動物傳播的病毒感染疾病日益受到重視。診斷方法正朝著整合式、多層次、分散式和數據驅動的方向發展，以支持患者照護和公共衛生監測。分子檢測、血清學、抗原檢測、定序和人工智慧分析發揮互補作用，但它們的價值取決於時機、檢驗驗證和健全的檢查室管治。

Abbott Laboratories
Abnova Corporation
ARUP Laboratories
Bio Lab Diagnostics（I）Private Limited
Bio-Rad Laboratories, Inc.
Bio-Techne
BIOGENIX INC. PVT. LTD.
bioMerieux SA
Biosynex SA
Clongen Laboratories, LLC
Coppe Laboratories
DiaSorin SpA
EIKEN CHEMICAL Co., Ltd.
EUROIMMUN AG by PerkinElmer Inc.
F. Hoffmann-La Roche Ltd
InBios International, Inc.
J Mitra & Co Ltd
Kephera Diagnostics
Merck KGaA
QIAGEN NV
Quest Diagnostics Incorporated
Sonora Quest Laboratories LLC
Thermo Fisher Scientific Inc.

Abbott Laboratories
Abnova Corporation
ARUP Laboratories
Bio Lab Diagnostics（I）Private Limited
Bio-Rad Laboratories, Inc.
Bio-Techne
BIOGENIX INC. PVT. LTD.
bioMerieux SA
Biosynex SA
Clongen Laboratories, LLC
Coppe Laboratories
DiaSorin SpA
EIKEN CHEMICAL Co., Ltd.
EUROIMMUN AG by PerkinElmer Inc.
F. Hoffmann-La Roche Ltd
InBios International, Inc.
J Mitra & Co Ltd
Kephera Diagnostics
Merck KGaA
QIAGEN NV
Quest Diagnostics Incorporated
Sonora Quest Laboratories LLC
Thermo Fisher Scientific Inc.

簡介目錄圖表

Product Code: MRR-4103B31E09C0

The Arthropod-borne Viral Infections Testing Market is projected to grow by USD 1.99 billion at a CAGR of 7.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.21 billion
Estimated Year [2026]	USD 1.29 billion
Forecast Year [2032]	USD 1.99 billion
CAGR (%)	7.36%

Arthropod-borne viral infections testing has become a critical pillar of global infectious disease preparedness as dengue, chikungunya, Zika, yellow fever, Japanese encephalitis, West Nile virus, tick-borne encephalitis, and other arboviral diseases expand across endemic and newly receptive geographies. These infections are transmitted primarily by mosquitoes, ticks, sandflies, and other vectors, with risk shaped by urbanization, climate variability, international travel, land-use change, gaps in vector control, and population immunity. Accurate and timely diagnostic testing is essential because many arboviral infections present with overlapping symptoms such as fever, rash, arthralgia, myalgia, headache, and neurological complications, making syndromic diagnosis insufficient for clinical management and public health response.

Testing strategies increasingly combine molecular assays, antigen detection, serology, genomic sequencing, and multiplex panels to support acute diagnosis, outbreak confirmation, surveillance, blood safety, vaccine policy, and differential diagnosis against malaria, leptospirosis, influenza-like illness, and other febrile conditions. Nucleic acid amplification tests are most useful during early viremia, while IgM and IgG serology are important after the initial acute phase; however, cross-reactivity among flaviviruses remains a recognized challenge, particularly in areas where dengue, Zika, yellow fever vaccination, and Japanese encephalitis exposure coexist. As health systems prioritize faster detection and stronger surveillance, demand for robust arbovirus diagnostics is being shaped by laboratory capacity, point-of-care access, quality assurance, regulatory oversight, and integration with national disease reporting systems.

Transformative Shifts in the Arbovirus Testing Landscape

The arthropod-borne viral infections testing landscape is being transformed by the convergence of high-burden endemic disease control, climate-sensitive vector expansion, and the need for rapid outbreak intelligence. Global health agencies have documented that dengue incidence has risen substantially over recent decades, with transmission now reported across more than 100 countries, underscoring the need for scalable diagnostics that can distinguish dengue from clinically similar infections. At the same time, West Nile virus activity in temperate regions, chikungunya resurgence in tropical and subtropical settings, and persistent yellow fever risk in parts of Africa and South America are reinforcing the value of integrated arboviral surveillance.

A major shift is occurring from single-pathogen testing toward multiplex and syndromic approaches capable of identifying multiple mosquito-borne and tick-borne viruses from a single sample. Public health laboratories are also adopting genomic sequencing to identify lineages, monitor viral evolution, and trace transmission chains during outbreaks. The rise of decentralized and near-patient testing is improving response time in remote or resource-limited settings, although confirmatory laboratory testing remains essential for surveillance-grade data. Blood screening, prenatal evaluation for Zika-related risk, neurological disease workups for West Nile virus, and travel medicine diagnostics are further expanding the use cases for arbovirus testing. These shifts are encouraging health systems to move from reactive outbreak testing toward year-round diagnostic readiness and vector-borne disease intelligence.

Cumulative Impact of Artificial Intelligence on Arbovirus Diagnostics

Artificial intelligence is creating a cumulative impact across arthropod-borne viral infections testing by strengthening outbreak prediction, diagnostic interpretation, laboratory workflow management, and surveillance analytics. AI-enabled models can combine vector distribution, rainfall, temperature, humidity, mobility, land-use, wastewater, clinical, and laboratory reporting data to identify high-risk transmission zones and support earlier public health interventions. This is especially relevant for dengue, Zika, chikungunya, West Nile virus, and tick-borne encephalitis, where vector ecology and seasonality influence testing demand.

Within diagnostics, machine learning is being explored to improve interpretation of multiplex assay results, reduce ambiguity caused by flavivirus serological cross-reactivity, and prioritize confirmatory testing when clinical and exposure histories suggest competing etiologies. AI-based laboratory information tools can improve sample triage, automate abnormal result flagging, support quality control, and accelerate reporting to surveillance networks. In genomic epidemiology, AI can assist with sequence classification, mutation monitoring, and cluster detection, enabling faster recognition of viral introductions or expansion. However, AI deployment must be governed by validated datasets, transparent performance metrics, privacy safeguards, and local epidemiological calibration. The highest-impact applications are those that augment expert interpretation rather than replace clinical, laboratory, and public health judgment.

Key Regional Insights Across Global Arbovirus Testing

Asia-Pacific remains one of the most important regions for arthropod-borne viral infections testing due to the high endemic burden of dengue, Japanese encephalitis, chikungunya, and emerging Zika risk in tropical and subtropical settings. Dense urban populations, monsoon patterns, Aedes mosquito proliferation, and expanding peri-urban habitats continue to drive diagnostic demand across Southeast Asia, South Asia, and parts of the Western Pacific. National programs increasingly rely on molecular confirmation, NS1 antigen testing, IgM serology, and sentinel surveillance to support outbreak detection and case classification.

North America demonstrates strong arbovirus testing capacity through public health laboratory networks, clinical reference testing, and seasonal surveillance for West Nile virus, travel-associated dengue and chikungunya, and tick-borne viral infections. The United States and Canada emphasize vector monitoring, blood safety, and neuroinvasive disease testing, while Mexico faces a dual role as both an endemic and cross-border surveillance setting for dengue and other Aedes-borne infections.

Latin America carries substantial diagnostic relevance due to recurring dengue outbreaks, chikungunya transmission, Zika-related congenital risk monitoring, and yellow fever surveillance in forested and peri-urban areas. Brazil, Mexico, and other countries in the region use laboratory confirmation to guide outbreak response and differentiate co-circulating arboviruses.

Europe has strengthened arbovirus testing in response to imported infections, local vector establishment, tick-borne encephalitis, West Nile virus outbreaks, and autochthonous dengue or chikungunya events in southern areas. Public health systems increasingly integrate travel medicine, vector surveillance, and molecular diagnostics to detect localized transmission.

The Middle East faces growing relevance for arbovirus diagnostics due to travel connectivity, Aedes vector suitability in selected urban zones, and climate conditions that can support vector-borne disease emergence. Testing is often linked to differential diagnosis of acute febrile illness, pilgrimage-associated preparedness, and imported case surveillance.

Africa remains central to arbovirus testing because of yellow fever, dengue, chikungunya, Rift Valley fever, and other vector-borne viral risks, yet laboratory access varies widely. Strengthening regional reference laboratories, integrated fever surveillance, and confirmatory testing capacity is essential for earlier outbreak recognition and improved disease burden characterization.

Key Group Insights for Arbovirus Testing Priorities

ASEAN countries are highly relevant to arthropod-borne viral infections testing because dengue is hyperendemic in several member states and chikungunya, Japanese encephalitis, and Zika surveillance remain important public health priorities. Cross-border mobility, urban density, and seasonal rainfall make harmonized laboratory reporting and regional outbreak intelligence essential for timely response.

The GCC is increasingly focused on arbovirus preparedness due to international travel, labor mobility, major mass gatherings, and climatic zones that can support vector presence in specific environments. Testing strategies in GCC countries emphasize imported case detection, differential diagnosis for febrile travelers, and laboratory readiness for emerging vector-borne threats.

The European Union has expanded arbovirus diagnostic coordination through surveillance of West Nile virus, tick-borne encephalitis, imported dengue and chikungunya, and sporadic local transmission linked to invasive mosquito species. EU public health systems place strong emphasis on laboratory quality standards, case definitions, and cross-border reporting.

BRICS countries collectively represent a large share of global arbovirus testing relevance because Brazil, India, China, Russia, and South Africa face diverse exposures ranging from dengue and chikungunya to tick-borne encephalitis, yellow fever risk, and travel-associated infections. Their diagnostic priorities reflect large populations, heterogeneous climates, and the need for both centralized and decentralized testing capacity.

G7 countries generally have advanced laboratory networks, blood safety infrastructure, and genomic surveillance capabilities, with testing demand driven by West Nile virus, tick-borne viral disease, imported arboviruses, and climate-linked vector expansion. Their role is also important in diagnostic standard setting, assay validation, and international outbreak support.

NATO member countries emphasize health security, deployment medicine, and operational readiness, making arbovirus diagnostics relevant for military personnel, humanitarian missions, and overseas deployments in endemic regions. Testing capabilities support force health protection, travel-associated infection management, and surveillance for diseases that can affect operational continuity.

Key Country Insights in Arthropod-borne Viral Infections Testing

The United States has extensive arbovirus testing needs driven by seasonal West Nile virus transmission, travel-associated dengue and chikungunya, congenital Zika surveillance history, and expanding concerns around tick-borne viral infections. Canada emphasizes West Nile virus surveillance, travel medicine diagnostics, and tick-borne disease monitoring, while Mexico faces significant dengue transmission alongside chikungunya and Zika surveillance needs.

Brazil is one of the most important national settings for arbovirus testing because dengue, Zika, chikungunya, and yellow fever surveillance intersect with large urban populations and ecologically diverse transmission zones. The United Kingdom focuses on imported arbovirus diagnosis, travel medicine, blood safety considerations, and public health monitoring of invasive mosquitoes. Germany, France, Italy, and Spain combine high-quality laboratory networks with growing attention to West Nile virus, tick-borne encephalitis, imported dengue, and localized transmission risk in warmer regions. France, Italy, and Spain are particularly relevant for monitoring Aedes-related autochthonous events in parts of southern Europe. Russia's arbovirus testing priorities include tick-borne encephalitis and other vector-associated infections across broad ecological zones.

China, India, and Japan represent major Asia-Pacific testing environments with distinct disease profiles. China monitors dengue, Japanese encephalitis, tick-borne viruses, and travel-related arboviruses; India faces recurrent dengue and chikungunya activity, Japanese encephalitis in specific areas, and the need for broad febrile illness differentiation; Japan maintains strong surveillance for Japanese encephalitis, imported dengue, and vector-borne disease preparedness. Australia combines advanced diagnostic infrastructure with surveillance for dengue in northern regions, Ross River virus, Barmah Forest virus, Japanese encephalitis emergence, and travel-associated infections. South Korea places emphasis on Japanese encephalitis, severe fever with thrombocytopenia syndrome, and imported arboviral disease detection, supported by strong laboratory and public health systems.

Actionable Recommendations for Arbovirus Diagnostic Leaders

Industry leaders should prioritize the development and deployment of diagnostics that address the real-world complexity of arboviral disease: short viremic windows, cross-reactive antibodies, co-circulating pathogens, and variable laboratory access. Multiplex molecular and serological panels should be designed around regional epidemiology, while confirmatory algorithms must account for flavivirus cross-reactivity and vaccination history. Investments in assay validation across diverse populations, sample types, and disease stages are essential for trustworthy results.

Leaders should strengthen partnerships with public health laboratories, hospitals, travel clinics, blood services, and vector surveillance programs to align testing with outbreak intelligence. Decentralized testing can improve early detection in endemic and remote settings, but it must be paired with quality assurance, digital reporting, and confirmatory pathways. Incorporating AI-enabled surveillance and laboratory analytics can improve early warning capacity, but models should be transparent, locally validated, and regularly updated. Supply chain resilience is also critical, especially during concurrent outbreaks when demand for reagents, extraction kits, controls, and trained personnel can surge. Finally, organizations should support workforce training, biosafety compliance, interoperability with disease reporting systems, and ethical data governance to ensure that arbovirus testing contributes to faster clinical care and stronger public health action.

Research Methodology for Evidence-based Arbovirus Testing Analysis

The research methodology for arthropod-borne viral infections testing should integrate verified public health evidence, clinical diagnostic guidelines, epidemiological surveillance data, regulatory references, and peer-reviewed scientific literature. Core inputs include disease-specific guidance from recognized health authorities, national surveillance bulletins, vector distribution records, laboratory testing algorithms, assay performance publications, and outbreak investigation reports. Data review should focus on confirmed disease occurrence, diagnostic use cases, testing technologies, sample timing, regional burden patterns, and surveillance infrastructure.

A robust methodology includes triangulation across multiple credible sources to validate trends in dengue, chikungunya, Zika, yellow fever, Japanese encephalitis, West Nile virus, tick-borne encephalitis, and other arboviruses. Qualitative assessment should examine clinical workflows, laboratory capacity, regulatory requirements, reimbursement context, and public health reporting systems. Technology evaluation should compare molecular testing, antigen detection, serology, sequencing, rapid tests, and multiplex assays based on intended use, timing of infection, specificity limitations, and confirmatory requirements. Regional and country insights should be interpreted through the lens of vector ecology, climate suitability, travel patterns, outbreak history, and healthcare infrastructure. This approach supports evidence-based analysis without relying on market sizing, market share, or forecasting.

Conclusion: Advancing Arbovirus Testing for Public Health Readiness

Arthropod-borne viral infections testing is becoming increasingly important as vector-borne diseases intensify across endemic regions and appear in new settings shaped by climate, mobility, urbanization, and ecological change. The diagnostic landscape is moving toward integrated, multiplex, decentralized, and data-driven approaches that can support both patient care and public health surveillance. Molecular assays, serology, antigen detection, sequencing, and AI-enabled analytics each play complementary roles, but their value depends on appropriate timing, validated performance, and strong laboratory governance.

Regional priorities differ substantially: Asia-Pacific and Latin America face high dengue and Aedes-borne disease pressure; North America and Europe combine imported disease management with West Nile virus and tick-borne surveillance; Africa requires strengthened confirmatory capacity for multiple high-impact arboviruses; and the Middle East emphasizes preparedness linked to travel and emerging vector suitability. For industry leaders, the path forward is clear: build reliable diagnostics, improve access, enhance interoperability, support surveillance integration, and design solutions that reflect local epidemiology. Evidence-based arbovirus testing will remain central to outbreak preparedness, clinical decision-making, and global health security.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Arthropod-borne Viral Infections Testing Market, by Test Type

7.1. Introduction
7.2. Antibody Testing
- 7.2.1. IgG Antibody
- 7.2.2. IgM Antibody
7.3. Antigen Testing
- 7.3.1. Elisa Antigen
- 7.3.2. Rapid Antigen
7.4. Molecular Testing
- 7.4.1. Conventional PCR
- 7.4.2. Isothermal Amplification
- 7.4.3. Real Time PCR

8. Arthropod-borne Viral Infections Testing Market, by Technology

8.1. Introduction
8.2. Immunoassay
- 8.2.1. Chemiluminescent Immunoassay
- 8.2.2. Lateral Flow Immunoassay
8.3. Next Generation Sequencing
- 8.3.1. Illumina Sequencing
- 8.3.2. Pyrosequencing
8.4. PCR Based Technologies
8.5. Rapid Diagnostic Test
- 8.5.1. Lateral Flow Assay
- 8.5.2. Optical Immunoassay

9. Arthropod-borne Viral Infections Testing Market, by Sample Type

9.1. Introduction
9.2. Blood Serum
9.3. Cerebrospinal Fluid
9.4. Plasma
9.5. Saliva
9.6. Whole Blood

10. Arthropod-borne Viral Infections Testing Market, by Disease Type

10.1. Introduction
10.2. Chikungunya
10.3. Dengue
10.4. West Nile
10.5. Yellow Fever
10.6. Zika

11. Arthropod-borne Viral Infections Testing Market, by End User

11.1. Introduction
11.2. Academic Institutions
11.3. Diagnostic Centers
11.4. Hospital Laboratories
11.5. Reference Laboratories
11.6. Research Institutes

12. Arthropod-borne Viral Infections Testing Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. Arthropod-borne Viral Infections Testing Market, by Group

13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC

14. Arthropod-borne Viral Infections Testing Market, by Country

14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Abbott Laboratories
16.2. Abnova Corporation
16.3. ARUP Laboratories
16.4. Bio Lab Diagnostics (I) Private Limited
16.5. Bio-Rad Laboratories, Inc.
16.6. Bio-Techne
16.7. BIOGENIX INC. PVT. LTD.
16.8. bioMerieux SA
16.9. Biosynex SA
16.10. Clongen Laboratories, LLC
16.11. Coppe Laboratories
16.12. DiaSorin S.p.A.
16.13. EIKEN CHEMICAL Co., Ltd.
16.14. EUROIMMUN AG by PerkinElmer Inc.
16.15. F. Hoffmann-La Roche Ltd
16.16. InBios International, Inc.
16.17. J Mitra & Co Ltd
16.18. Kephera Diagnostics
16.19. Merck KGaA
16.20. QIAGEN N.V.
16.21. Quest Diagnostics Incorporated
16.22. Sonora Quest Laboratories LLC
16.23. Thermo Fisher Scientific Inc.

簡介目錄圖表

LIST OF FIGURES

FIGURE 1. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

TABLE 1. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IGG ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IGG ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IGG ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IGM ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IGM ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IGM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIGEN TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIGEN TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIGEN TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ELISA ANTIGEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ELISA ANTIGEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ELISA ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RAPID ANTIGEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RAPID ANTIGEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RAPID ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MOLECULAR TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MOLECULAR TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MOLECULAR TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CONVENTIONAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CONVENTIONAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CONVENTIONAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ILLUMINA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ILLUMINA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ILLUMINA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PYROSEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PYROSEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PYROSEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PCR BASED TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PCR BASED TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PCR BASED TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL OPTICAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL OPTICAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL OPTICAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BLOOD SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BLOOD SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BLOOD SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CHIKUNGUNYA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CHIKUNGUNYA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CHIKUNGUNYA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DENGUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DENGUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL DENGUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL WEST NILE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL WEST NILE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL WEST NILE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL YELLOW FEVER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL YELLOW FEVER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL YELLOW FEVER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ZIKA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ZIKA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ZIKA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 128. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 129. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 130. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 131. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 133. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 134. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 135. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 165. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 166. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 171. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 172. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 173. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 187. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 188. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 189. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 190. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 191. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 192. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 193. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 194. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 195. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 196. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 197. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 198. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 200. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 201. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 202. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 203. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 204. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 205. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 206. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 207. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 208. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 209. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 210. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 212. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 213. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 214. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 215. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 216. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 218. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 219. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 220. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 221. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 222. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 236. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 237. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 238. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 239. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 240. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 241. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 242. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 243. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 244. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 245. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 246. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 248. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 249. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 250. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 251. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 252. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 253. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 254. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 255. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 256. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 257. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 258. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 260. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 261. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 262. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 263. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 264. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 265. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 266. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 267. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 268. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 269. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 270. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 271. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 285. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 286. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 287. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 288. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 289. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 290. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 291. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 292. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 293. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 294. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 295. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 296. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 297. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 298. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 299. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 300. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 301. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 302. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 303. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 304. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 305. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 306. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 307. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 309. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 310. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2032 (USD MILLION)
TABLE 311. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2032 (USD MILLION)
TABLE 312. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2032 (USD MILLION)
TABLE 313. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 314. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 315. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQU